Fig. 2.1 Major immunopathological and genetic events occurring during carcinogenesis. Upon chronic inflammatory stimuli exposure, normal cells undergo transformation into precancerous cells. Local inflammation induces recruitment of myeloid-derived cells that…
© Springer International Publishing AG 2018Laurence Zitvogel and Guido Kroemer (eds.)Oncoimmunologyhttps://doi.org/10.1007/978-3-319-62431-0_43 43. Concluding Remarks Pedro Romero1 and Wolf H. Fridman1 (1) Ludwig Cancer Research Center at University of Lausanne, Switzerland and Cordeliers Research Center, Paris, France …
Fig. 39.1 A workflow of immunotherapy discovery and combinatorial treatment approaches in neurooncology References 1. Ousman SS, Kubes P. Immune surveillance in the central nervous system. Nat Neurosci. 2012;15:1096–101.CrossrefPubMed 2….
Advanced melanoma Outcome Publication (Ref) gp100 vs ipilimumab vs ipilimumab + gp100 Ipilimumab 3 mg/kg approved OS benefit Hodi et al. [18] DTIC vs DTIC + ipilimumab Ipilimumab 10 mg…
Fig. 14.1 Mode of action of synthetic long peptide vaccination. The tumor-associated antigens are efficiently delivered by SLP easily obtaining access to DC in the vaccine injection area. Antigen-loaded DC…
Fig. 27.1 The immunogenicity of E. hirae. E. hirae resides in the jejunum and colon in about 25% individuals. It is very dominant in mouse guts at Gustave Roussy Villejuif….
Fig. 7.1 Generation of extracellular ATP and adenosine in the tumor microenvironment (TME). (1) In response to hypoxia, cells in the TME release ATP through either ATP-binding casettes, Pannexin-1 or…
Fig. 26.1 Constitutive and activation-induced co-stimulatory members of the TNF and TNFR families expressed on T cells, NK cells, and antigen-presenting cells (APCs). Schematic representation of an immune synapse between…
© Springer International Publishing AG 2018Laurence Zitvogel and Guido Kroemer (eds.)Oncoimmunologyhttps://doi.org/10.1007/978-3-319-62431-0_25 25. Innate Immune Receptors in the Regulation of Tumor Immunity Sho Hangai1, 2, Yoshitaka Kimura1, 2, Tadatsugu Taniguchi1, 2 and Hideyuki Yanai1, 2 (1) Department of Molecular Immunology,…
Setting Name Study design Primary endpoints Estimated end of study First line CAG209-214 NCT02231749 Nivolumab + ipilimumab vs Sutent Phase III PFS and OS June 2019 First line IMmotion 151…
